background

About Us

Developing products that are first-in-class with unique mechanism of action and are different from those of existing therapies

Pharmazz, Inc.

Pharmazz, Inc. is an innovative biopharmaceutical company with an approved product, promising drug pipeline and a seasoned management team. It is a Delaware Corporation based in Willowbrook, Illinois, USA focused on discovering, acquiring, developing, and commercializing therapeutics that target critical care medicine. Pharmazz India Private Limited a majority owned subsidiary of Pharmazz, Inc. obtained marketing authorization of Lyfaquin® (INN: Centhaquine) in India.

Pharmazz has licensed exclusive worldwide rights to several molecules indicated for critically ill patients from Midwestern University, Downers Grove, USA. The company has a strong patent position and robust pipeline in different stages of clinical development.

about

The company is developing three novel first-in-class drug products across multiple critical care indications. Its lead product, Centhaquine, is for Hypovolemic Shock where a new therapeutic is greatly needed. Pharmazz’s second compound, Sovateltide, is for cerebral ischemic stroke, Alzheimer’s disease, and other neurodegenerative diseases. A third compound is being developed for treatment of diabetic ketoacidosis and to eliminate opioid tolerance.

RoadMap ↓

2020
Centhaquine Market Approval (India) - May
Lyfaquin® (centhaquine) launched - November
2019
Sovateltide Phase III for Stroke - July
2018
Sovateltide Phase II for Acute Spinal Cord Injury - October
Centhaquine Phase III - December
2017
Sovateltide Phase II for Stroke - August
Sovateltide Phase II for Alzheimer’s disease - August
2016
Sovateltide Phase I - July
Centhaquine Phase II - December
2014
Licensing agreement with University of Illinois - January
Centhaquine Phase I - September
2011
Licensing agreement with Midwestern The University - January
Pharmazz India Private Limited started - March
2010
Incorporated - October